News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
740,237 Results
Type
Article (51887)
Company Profile (312)
Press Release (688038)
Section
Business (215777)
Career Advice (3044)
Deals (37476)
Drug Delivery (112)
Drug Development (85658)
Employer Resources (186)
FDA (17043)
Job Trends (15994)
News (366882)
Policy (35650)
Tag
Academia (2831)
Alliances (53848)
Alzheimer's disease (1363)
Approvals (16977)
Artificial intelligence (202)
Bankruptcy (377)
Best Places to Work (12161)
Biotechnology (199)
Breast cancer (218)
Cancer (1664)
Cardiovascular disease (137)
Career advice (2544)
CAR-T (121)
Cell therapy (345)
Clinical research (68592)
Collaboration (645)
Compensation (322)
COVID-19 (2773)
C-suite (146)
Data (1528)
Diabetes (211)
Diagnostics (6495)
Earnings (87517)
Employer resources (163)
Events (115818)
Executive appointments (531)
FDA (17870)
Funding (566)
Gene therapy (244)
GLP-1 (727)
Government (4741)
Healthcare (19855)
Infectious disease (2874)
Inflammatory bowel disease (127)
Interviews (557)
IPO (16958)
Job creations (4273)
Job search strategy (2119)
Layoffs (474)
Legal (8876)
Lung cancer (250)
Manufacturing (240)
Medical device (13837)
Medtech (13842)
Mergers & acquisitions (20796)
Metabolic disorders (569)
Neuroscience (1770)
NextGen: Class of 2025 (7043)
Non-profit (4817)
Northern California (1929)
Obesity (326)
Opinion (251)
Patents (146)
People (60026)
Phase I (21253)
Phase II (30138)
Phase III (22566)
Pipeline (643)
Postmarket research (2848)
Preclinical (9039)
Radiopharmaceuticals (251)
Rare diseases (324)
Real estate (6489)
Regulatory (23757)
Research institute (2534)
Resumes & cover letters (498)
Southern California (1677)
Startups (3936)
United States (17563)
Vaccines (661)
Weight loss (243)
Date
Today (112)
Last 7 days (621)
Last 30 days (2538)
Last 365 days (36123)
2025 (2522)
2024 (36573)
2023 (41481)
2022 (52731)
2021 (57397)
2020 (56249)
2019 (49306)
2018 (37409)
2017 (34542)
2016 (34356)
2015 (40167)
2014 (34155)
2013 (29372)
2012 (31498)
2011 (32166)
2010 (30450)
Location
Africa (934)
Arizona (221)
Asia (42589)
Australia (7005)
California (4439)
Canada (1606)
China (385)
Colorado (202)
Connecticut (216)
Europe (92673)
Florida (638)
Georgia (160)
Illinois (457)
Indiana (262)
Maryland (728)
Massachusetts (3464)
Michigan (191)
Minnesota (333)
New Jersey (1252)
New York (1271)
North Carolina (844)
Northern California (1929)
Ohio (164)
Pennsylvania (1029)
South America (1324)
Southern California (1677)
Texas (657)
Utah (129)
Washington State (450)
740,237 Results for "kinetix pharmaceuticals inc merged with amgen see amgen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year.
January 15, 2025
·
4 min read
·
Tristan Manalac
Weight Loss
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated readout sent the company’s shares tumbling.
November 26, 2024
·
2 min read
·
Annalee Armstrong
Regulatory
FDA Pushes Back PDUFA Dates for Amgen and Intercept
The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals’ Ocaliva for primary biliary cholangitis.
October 18, 2024
·
2 min read
·
Tristan Manalac
Manufacturing
Amgen to Add 370 New Jobs in North Carolina With $1B Manufacturing Investment
It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity as it prepares to enter the obesity space with MariTide.
December 6, 2024
·
2 min read
·
Tristan Manalac
Obesity
Amgen Suffers Surprise Blow as New Bone Density Safety Concerns for MariTide Surface
Cantor Fitzgerald analyst Olivia Brayer found supplementary bone mineral density data for Amgen’s obesity candidate MariTide that could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.
November 13, 2024
·
2 min read
·
Tristan Manalac
Pipeline
Amgen Whets Investors’ Appetites for MariTide Obesity Data by End of Year
While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on the highly anticipated MariTide Phase II results slated for late 2024, according to BMO Capital Markets analyst Evan Seigerman.
October 31, 2024
·
2 min read
·
Tristan Manalac
Legal
Amgen Faces Class Action Lawsuit for Allegedly Hiding $10.7B Tax Bill From Investors
Amgen’s motion for dismissal was denied after a New York judge agreed the company did not sufficiently disclose to shareholders back taxes and penalties owed to the Internal Revenue Service.
October 2, 2024
·
2 min read
·
Tristan Manalac
Legal
Amgen Gets Legal Win in Eylea Patent Row With Regeneron
Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea.
September 24, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
January 6, 2025
·
7 min read
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival, calling it the “major efficacy outcome” of the trial.
January 17, 2025
·
2 min read
·
Tristan Manalac
1 of 74,024
Next
